LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 07 Apr 2025
Image: BIOTIA-ID is an NGS platform that accurately and sensitively diagnoses infectious disease-causing pathogens (Photo courtesy of Adobe Stock)
Image: BIOTIA-ID is an NGS platform that accurately and sensitively diagnoses infectious disease-causing pathogens (Photo courtesy of Adobe Stock)

With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions. Now, a new collaboration aims to address one of the most pressing challenges in modern healthcare: timely and precise identification of infectious pathogens.

Biotia (New York, NY, USA) has entered into a joint development agreement with Mayo Clinic (Rochester, MN, USA) to propel precision medicine in infectious disease diagnostics. This collaboration seeks to combine Mayo Clinic's clinical expertise and diagnostics with Biotia's innovative microbial analytics platform to enhance patient care through faster, more accurate, and comprehensive infectious disease diagnostic solutions. Biotia's cutting-edge AI-powered sequence analysis capabilities will be used to identify and characterize pathogens isolated from clinical specimens, providing laboratories and clinicians with detailed strain level pathogen identities and actionable information.

Mayo Clinic will contribute its expertise in microbial diagnostics, clinical application, data interpretation, and patient care to ensure the solutions are optimized for real-world clinical use. Biotia's platform integrates next-generation sequencing with a curated pathogen database and advanced bioinformatics, delivering rapid and reliable results that empower clinicians to make informed treatment decisions. The collaboration is expected to yield new diagnostic solutions that will be piloted at Mayo Clinic, with the potential for broader deployment across healthcare systems worldwide.

"Together, we aim to reduce diagnostic uncertainty, enhance patient outcomes, and tackle global health challenges using precision diagnostics," said Dr. Niamh O'Hara, CEO and co-founder of Biotia.

Related Links:
Biotia
Mayo Clinic

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more